NAVCO Pharmaceuticals Income Statement

Financials in millions CAD. Fiscal year is October - September.

Millions CAD. Fiscal year is Oct - Sep.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Revenue	-	-	-	0.06	0.02
Revenue Growth (YoY)	-	-	-	278.32%	-
Gross Profit	-	-	-	0.06	0.02
Selling, General & Admin	0.05	0.76	1.4	0.47	0.5
Amortization of Goodwill & Intangibles	-	0.01	0.01	0.01	0
Operating Expenses	0.05	1.57	1.44	0.51	0.53
Operating Income	-0.05	-1.57	-1.44	-0.45	-0.51
Interest Expense	-0.01	-0.02	-0.01	-0.01	-0.01
Other Non Operating Income (Expenses)	-0.02	-0.03	-0.03	-	-
EBT Excluding Unusual Items	-0.08	-1.62	-1.48	-0.47	-0.53
Asset Writedown	-	-0.11	-	-	-
Other Unusual Items	-	-	-0.67	-	-
Pretax Income	-0.08	-1.72	-2.15	-0.47	-0.53
Net Income	-0.08	-1.72	-2.15	-0.47	-0.53
Net Income to Common	-0.08	-1.72	-2.15	-0.47	-0.53
Shares Outstanding (Basic)	57	52	30	21	14
Shares Outstanding (Diluted)	57	52	30	21	14
Shares Change (YoY)	9.65%	72.37%	41.49%	47.34%	-
EPS (Basic)	-0.00	-0.03	-0.07	-0.02	-0.04
EPS (Diluted)	-0.00	-0.03	-0.07	-0.02	-0.04
Free Cash Flow	-0.02	-0.25	-1.78	-0	-0.31
Free Cash Flow Per Share	-	-0.01	-0.06	-	-0.02
Gross Margin	-	-	-	100.00%	100.00%
Operating Margin	-	-	-	-766.48%	-3309.64%
Profit Margin	-	-	-	-791.92%	-3389.75%
Free Cash Flow Margin	-	-	-	-7.72%	-2027.27%
EBITDA	-0.02	-1.54	-1.4	-0.42	-0.49
D&A For EBITDA	0.03	0.03	0.04	0.03	0.02
EBIT	-0.05	-1.57	-1.44	-0.45	-0.51

Source: S&P Global Market Intelligence. Standard template. Financial Sources.